For better understanding of anti-LILRB4 function in MM progression, we subcutaneously implanted ARP-1 and MM1.S cells into NOG-SCID mice and treated them with anti-LILRB4-specific monoclonal antibodies (C84) [20] or IgG control antibodies. Here, LILRB4 is linked to Miyoshi myopathy.